content: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
                           Date of Report: April 30, 2000
  
                              IVES HEALTH COMPANY, INC.
  
            Oklahoma                  0-28227                   73-1430235
            --------                  -------                   ----------
    State of Incorporation       Commission File No.        IRS Employer ID No.
  
  
        817 North J.M. Davis,  Claremore, Oklahoma                74017
         (Address of principal executive offices)               (Zip Code)
  
                                   (918) 283-1226
                (Registrant's telephone number, including area code)
  
  <PAGE>
  
  Item 2. Acquisition or Disposition of Assets.
  ---------------------------------------------
  
       (a)  On April 30, 2000, Ives Formulation  Company,  Inc., a newly organized
            and wholly owned  Oklahoma  subsidiary  of Ives Health  Company,  Inc.
            ("Ives"),  purchased certain assets from International Formulation and
            Manufacturing  Company,  Inc.,  of San Diego,  CA ("IFM").  IFM is the
            primary  supplier of certain  products  private  labeled by Ives.  The
            purchase  price  consisted of $502,000 in cash, a promissory  note for
            $150,000  payable by Ives at $25,000 per month for 6 months  beginning
            May 1, 2000, and 150,000  shares of Ives common stock.  The Ives stock
            was issued in a  transaction  exempt  from  registration  pursuant  to
            Section  4(2) of the  Securities  Act.  No  affiliate  of  Ives  had a
            financial interest in IFM.
  
       (b)  The assets purchased consisted of various manufacturing equipment used
            to mix, tabletize,  encapsulate,  and package natural non-prescription
            medicines;  certain  inventory of finished goods and work in progress,
            certain  office  furniture,  computers,  office  machines,  laboratory
            equipment,   various  intellectual  property  rights,   including  the
            exclusive  right to certain  formulas of products  which Ives  private
            labels. The company intends to continue the use of the above assets.
  
       (c)  Dr.  Jack  Watkins,  founder  and  principal  shareholder  of IFM  and
            inventor and owner of the  intellectual  property  rights,  along with
            other key  employees  of IFM,  agreed to become  employed by Ives as a
            result of this transaction.
  
       (d)  As a result of this  purchase,  Ives now has control of the  equipment
            and  personnel  to supply Ives with the  products it supplies to Ives'
            customers.
  
  Item 6. Resignations of Registrant's Directors
  ----------------------------------------------
  
       On April 10, 2000,  Tony Fauver  resigned as a director of Ives. No dispute
       exists  between Ives and Mr.  Fauver.  Mr.  Fauver will  continue to be the
       Operations Manager and in charge of Quality Control.
  
  
                                      SIGNATURE
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned thereunto duly authorized.
  
                                                   IVES HEALTH COMPANY, INC.
  
                                                   By S/ Michael Harrison
  Date:   May 12, 2000                             Michael Harrison, CEO
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "IVES HEALTH COMPANY, INC.", "secsgml_size_bytes": 3625}]
metadata_filer: {"company-data": {"conformed-name": "IVES HEALTH CO INC", "cik": "0001098844", "assigned-sic": "2833", "irs-number": "731430235", "state-of-incorporation": "OK", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28227", "film-number": "630103"}, "business-address": {"street1": "817 NORTH J M DAVIS", "city": "CLAREMORE", "state": "OK", "zip": "74017", "phone": "9182831226"}, "mail-address": {"street1": "817 NORTH J M DAVIS", "city": "CLAREMORE", "state": "OK", "zip": "74017"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
                           Date of Report: April 30, 2000
  
                              IVES HEALTH COMPANY, INC.
  
            Oklahoma                  0-28227                   73-1430235
            --------                  -------                   ----------
    State of Incorporation       Commission File No.        IRS Employer ID No.
  
        817 North J.M. Davis,  Claremore, Oklahoma                74017
         (Address of principal executive offices)               (Zip Code)
  
                                   (918) 283-1226
                (Registrant's telephone number, including area code)
  Item 2. Acquisition or Disposition of Assets.
  ---------------------------------------------
  
       (a)  On April 30, 2000, Ives Formulation  Company,  Inc., a newly organized
            and wholly owned  Oklahoma  subsidiary  of Ives Health  Company,  Inc.
            ("Ives"),  purchased certain assets from International Formulation and
            Manufacturing  Company,  Inc.,  of San Diego,  CA ("IFM").  IFM is the
            primary  supplier of certain  products  private  labeled by Ives.  The
            purchase  price  consisted of $502,000 in cash, a promissory  note for
            $150,000  payable by Ives at $25,000 per month for 6 months  beginning
            May 1, 2000, and 150,000  shares of Ives common stock.  The Ives stock
            was issued in a  transaction  exempt  from  registration  pursuant  to
            Section  4(2) of the  Securities  Act.  No  affiliate  of  Ives  had a
            financial interest in IFM.
  
       (b)  The assets purchased consisted of various manufacturing equipment used
            to mix, tabletize,  encapsulate,  and package natural non-prescription
            medicines;  certain  inventory of finished goods and work in progress,
            certain  office  furniture,  computers,  office  machines,  laboratory
            equipment,   various  intellectual  property  rights,   including  the
            exclusive  right to certain  formulas of products  which Ives  private
            labels. The company intends to continue the use of the above assets.
  
       (c)  Dr.  Jack  Watkins,  founder  and  principal  shareholder  of IFM  and
            inventor and owner of the  intellectual  property  rights,  along with
            other key  employees  of IFM,  agreed to become  employed by Ives as a
            result of this transaction.
  
       (d)  As a result of this  purchase,  Ives now has control of the  equipment
            and  personnel  to supply Ives with the  products it supplies to Ives'
            customers.
  
  Item 6. Resignations of Registrant's Directors
  ----------------------------------------------
  
       On April 10, 2000,  Tony Fauver  resigned as a director of Ives. No dispute
       exists  between Ives and Mr.  Fauver.  Mr.  Fauver will  continue to be the
       Operations Manager and in charge of Quality Control.
  
                                      SIGNATURE
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned thereunto duly authorized.
  
                                                   IVES HEALTH COMPANY, INC.
  
                                                   By S/ Michael Harrison
  Date:   May 12, 2000                             Michael Harrison, CEO